COMMUNIQUÉS West-GlobeNewswire

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights
18/03/2026
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD [...]
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
18/03/2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF [...]
TOMI Environmental Solutions Disrupts Food Safety Sector with 95% Reduction in Sanitation Testing Costs
18/03/2026
TOMI Capitalizes on Global Food Safety Demand FREDERICK, Md., March 18, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination [...]
LiveWorld Reports 2025 Financial Results
18/03/2026
LiveWorld continues to increase its AI investment CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025. Twelve Months [...]
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
18/03/2026
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators’ expertise [...]
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
18/03/2026
Approval marks a historic milestone for Americans living with ssAR who are at high risk for surgery and previously had no dedicated transcatheter treatment option IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- [...]
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
18/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meeting of Stockholders [...]
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
18/03/2026
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full [...]
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
18/03/2026
ORION CORPORATION PRESS RELEASE 18 March 2026 at 10:00 EET Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership Orion Corporation (“Orion Pharma”) and CMI - Martti Ahtisaari [...]
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
18/03/2026
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing [...]
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18/03/2026
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from additional [...]
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
18/03/2026
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures [...]
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
18/03/2026
43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice. Veterinarians are seen as the most trusted source of pet health advice. “Small acts of [...]
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
18/03/2026
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt [...]
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3
18/03/2026
Le venglusta t de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026 . La Food and Drug Administration (FDA) des États-Unis a accordé la [...]
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026
Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au [...]
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR
18/03/2026
Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en [...]
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
18/03/2026
Sanofi’s venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to [...]

Pages